U.S. Markets close in 1 hr 25 mins
  • S&P 500

    4,314.36
    -118.63 (-2.68%)
     
  • Dow 30

    33,685.71
    -899.17 (-2.60%)
     
  • Nasdaq

    14,559.26
    -484.71 (-3.22%)
     
  • Russell 2000

    2,169.89
    -66.98 (-2.99%)
     
  • Crude Oil

    69.96
    -2.01 (-2.79%)
     
  • Gold

    1,762.00
    +10.60 (+0.61%)
     
  • Silver

    22.16
    -0.14 (-0.63%)
     
  • EUR/USD

    1.1729
    -0.0003 (-0.0235%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • Vix

    27.41
    +6.60 (+31.72%)
     
  • GBP/USD

    1.3652
    -0.0086 (-0.6239%)
     
  • USD/JPY

    109.3400
    -0.5550 (-0.5050%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,088.66
    -45.73 (-4.03%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - May 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.

Class Period: June 15, 2020 and April 4, 2021
Lead Plaintiff Deadline: June 18, 2021

Learn more about your recoverable losses in ACAD:
http://www.kleinstocklaw.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?id=15546&from=5

The filed complaint alleges that Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders have until June 18, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the ACAD lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83128